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use#LAARetinal degeneration, such as retinitis pigmentosa (RP) 
and age-related macular degeneration (AMD), either inher-
ited or age related, is the most common and irreversible 
end point for the degeneration of photoreceptors [1]. Stem 
cell (SC)-based therapy is now widely considered to be a 
potential therapeutic approach, providing the opportunity to 
repair and replace non-functioning neuroretinal cells [2-4]. 
Several types of SCs are currently being used within this 
field of study, including retinal progenitor cells (RPCs) [5], 
embryonic stem cells (ESCs) [6], induced pluripotent stem 
cells (iPSCs) [7], mesenchymal stem cells (MSCs) [8], and 
very small embryonic-like (VSEL) stem cells [9].
The donor SCs modulate cell survival by producing 
various neurotropic factors that contribute to implementing 
the cell replacement strategy. However, the environment 
surrounding the recipient adult retina plays an important 
role in inhibiting retinal progenitor cell integration and 
differentiation. Immunorejection is still a major problem in 
transplantation. Although the eye is frequently regarded as 
an immunoprivileged site, containing the anterior chamber, 
vitreous cavity, and subretinal space, the eye should actu-
ally be viewed as a partially immunoprivileged site, since 
it appears to show the rejection of cells delivered by trans-
plantation in the subretinal space over the long term [10]. 
Therefore, classic immunosuppressive drug therapies, or 
alternatives, could be used to enhance and prolong trans-
planted cell survival [11].
Cyclosporin A (CsA) has recently assumed the posi-
tion as one of the most frequently used immunosuppressive 
drugs to prevent rejection in transplant surgery, dramatically 
improving patients’ prognosis. CsA has been widely used 
by ophthalmologists, systematically and locally, for various 
indications in ocular disease [12]. These uses include corneal 
graft rejection, autoimmune eye conditions, and dry eye 
syndrome. Although this technique is widely used, it is poorly 
understood [13,14].
The primary purpose of our study was to investigate the 
effectiveness of CsA in modulating functional and structural 
responses to hRPCs in B6 mice, which will lay the ground-
work for the further study of different genotypes of rhodopsin 
Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271>
Received 21 November 2013 | Accepted 17 September 2014 | Published 19 September 2014
© 2014 Molecular Vision
1271
Functional and morphological analysis of the subretinal injection 
of human retinal progenitor cells under Cyclosporin A treatment
Rui Huang,1,2 Petr Baranov,2 Kunbei Lai,1,2 Xinmei Zhang,2 Jian Ge,,1 Michael J. Young2
1Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou, China; 
2Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, MA
Purpose: The purpose of this study is to evaluate the functional and morphological changes in subretinal xenografts 
of human retinal progenitor cells (hRPCs) in B6 mice treated with Cyclosporin A (CsA; 210 mg/l in drinking water).
Methods: The hRPCs from human fetal eyes were isolated and expanded for transplantation. These cells, with green 
fluorescent protein (GFP) at 11 passages, were transplanted into the subretinal space in B6 mice. A combination of 
invasive and noninvasive approaches was used to analyze the structural and functional consequences of the subretinal 
injection of the hRPCs. The process of change was monitored using spectral domain optical coherence tomography 
(SDOCT), histology, and electroretinography (ERG) at 3 days, 1 week, and 3 weeks after transplantation. Cell counts 
were used to evaluate the survival rate with a confocal microscope. ERGs were performed to evaluate the physiologic 
changes, and the structural changes were evaluated using SDOCT and histological examination.
Results: The results of the histological examination showed that the hRPCs gained a better survival rate in the mice 
treated with CsA. The SDOCT showed that the bleb size of the retinal detachment was significantly decreased, and 
the retinal reattachment was nearly complete by 3 weeks. The ERG response amplitudes in the CsA group were less 
decreased after the injection, when compared with the control group, in the dark-adapted and light-adapted conditions. 
However, the cone-mediated function in both groups was less affected by the transplantation after 3 weeks than the 
rod-mediated function.
Conclusions: Although significant functional and structural recovery was observed after the subretinal injection of the 
hRPCs, the effectiveness of CsA in xenotransplantation may be a novel and potential approach for increasing retinal 
progenitor cell survival.
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mice. Additionally, we will explore the survival rate of hRPCs 
after 3 weeks in these mice.
METHODS
Recipient animals: C57BL/6J mice (Jackson Laboratory, Bar 
Harbor, ME) at 4–5 weeks of age were prepared in a 12 h:12 h 
light-dark cycle room, and provided with standard water and 
food. The mice were divided into two groups: mice treated 
with CsA (210 mg/l; n = 45) and mice without CsA (n = 55). 
The animals in each group were euthanized by CO2 inhala-
tion, and their eyes were surgically enucleated at different 
time points after the subretinal injection of hRPCs: day 0 
(n = 10), day 3 (n = 15), week 1 (n = 15), and week 3 (n = 
15). Histological evaluations (histology, optical coherence 
tomography [OCT]) and functional changes (electroretinog-
raphy [ERG]) at each time point were recorded to monitor the 
changes after the transplantation of the hRPCs. All experi-
mental procedures were in accordance with the guidelines 
defined by the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research, and all experimental proto-
cols were approved by the Animal Care and Use Committee 
of the Schepens Eye Research Institute.
Drug preparation: A stock solution of CsA (21 g/l) was 
diluted in drinking water to make a 210 mg/l solution [15-17]. 
This medication was administered at the beginning of day 
1, before the injections, and was maintained throughout the 
duration of the study (water bottles were replaced every 
3 days to maintain the drug concentration). To ensure the 
appropriate and healthy state of the mice, the animals were 
visually inspected (behavior and skin) and weighed at the 
beginning and every day during the entire process of the 
study.
Cell isolation and culture: The hRPCs were harvested from 
the neuroretinas of human fetal eyes (14–18 weeks gestational 
age; GA) as previously described [18,19]: the neuro-retinas 
were dissected from each eye and minced into small pieces; 
then the tissue was dissociated enzymatically using collage-
nase (0.1%; Sigma-Aldrich, St. Louis, MO) by gently stir-
ring at 300 ×g for 20 min using magnetic stirring bar. The 
supernatant containing the dissociated cells was transferred, 
and the same isolation for the remaining undissociated tissue 
was repeated for a total of four cycles. Finally, the released 
cells were collected, centrifuged at 300 ×g, and resuspended 
in Ultraculture medium (Lonza, Basel, Switzerland), supple-
mented with 20 ng/ml epidermal growth factor (EGF; Sigma-
Aldrich), 20 ng/ml basic fibroblastic growth factor (bFGF; 
Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Invitrogen), 50 
g/ml gentamicin (Invitrogen). The cells were fed by replacing 
half the volume with fresh media every other day, and were 
passaged when they achieved 70–85% confluence. Then, the 
cells went through the following process: They were washed 
with Hanks-Balanced Salt Solution (HBSS; Invitrogen), 
dissociated with 0.25% trypsin (Sigma-Aldrich), inhibited 
by defined trypsin inhibitor (Invitrogen), centrifuged at 300 
×g for 5 min, and plated in new fibronectin-coated flasks. At 
11 passages, the cells were used for transplantation.
Retroviral vector transduction: At passage 6 hRPC were 
transfected with GFP, under the control of EF1a promoter 
to achieve stable expression (Gentarget Inc., San Diego, 
CA). For transfection 1,5 million cells were plated in a T75 
flask, and 24 h later medium was replaced with 5 ml of warm 
medium containing lentiviral particles (2x106 IFU total, 
MOI ≈ 1.2) and 2.5 μg/ml polybrene. 24 h later cells were 
washed, re-plated and GFP-expressing cells were selected 
by Puromycin (3 μg/ml, Sigma-Aldrich) to establish a stable 
expressing cell line. Cells were expanded to passage 11 for 
transplantation.
Subretinal transplantation: The recipient B6 mice were 
anesthetized with an intraperitoneal injection of ketamine 
(120 mg/kg) and xylazine (20 mg/kg), followed by local 
anesthetization with 0.5% proparacaine (Accutome, Malvern, 
PA), and pupillary dilation with 1% tropicamide (Akorn, 
Lake Forest, IL). A conjunctival incision was made using 
microscissors to expose the sclera of the eye. Then a small 
self-sealing sclerotomy was performed with the tip of a 
30-gauge needle (BD) cutting tangentially into the subretinal 
space and then was withdrawn. For this study, fresh hRPCs 
were prepared as a suspension of retinal cells in a non-toxic 
excipient, N-acetyl-cysteine (Sigma-Aldrich; HBSS-NAC), 
at a concentration of 50 million cells per mL (50 k/μl, 97% 
viability). These cells were GFP (+) cells, suspended in cell 
injection buffer, consisting of HBSS-NAC with a pH of 
7.4. One μl of the HBSS suspension containing the hRPCs 
(approximately 50,000 cells) was inserted through the scle-
rotomy in a tangential direction into the subretinal space. 
This was achieved by using a glass microneedle connected 
to a 50-μl microsyringe (Hamilton, Reno, NV) via polyeth-
ylene tubing. During the entire procedure, a heating pad 
was used to maintain the temperature of the mice until they 
recovered. Then they were returned to their normal housing 
after transplantation.
Tissue preparation and histology: The recipient B6 mice 
in both groups were euthanized at 0, 3, 7, and 21 days after 
transplantation. The eyes were enucleated and immersion 
fixed in 4% paraformaldehyde for 24 h at 4 °C, followed by 
cryoprotection in 10% and 30% sucrose in a 0.1% phosphate 
buffer. The eyes were sectioned at 12 μm on a cryostat. Some 
sections were stained with 4’,6-diamidino-2-phenylindole Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
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dihydrochloride (DAPI), viewed under fluorescent illumina-
tion, and examined with confocal microscopy (Leica SP2, 
Leica Microsystems GmbH, Wetzlar, Germany).
Optical coherence tomography recordings: The mice were 
anesthetized with an intraperitoneal injection of a mixture 
of ketamine (100 mg/kg) and xylazine (20 mg/kg), and were 
kept warm on a heating pad. The pupils were dilated with 
topical tropicamide. A rectangular volume scan, focusing 
on the injection site and the bleb formed by retinal detach-
ment, was applied using a spectral domain optical coherence 
tomography (SDOCT) system (Bioptigen Spectral Domain 
Ophthalmic Imaging System; Bioptigen, Durham, NC). A 
rectangular, or raster volume scan composed of a series of 
parallel B-scans, served as an annular cross-sectional view 
around the point of interest in the tissue. Finally, the imaging 
and data were exported and analyzed.
Electroretinographic recordings: Both groups (CsA and 
non-CsA) of B6 mice were dark-adapted overnight and anes-
thetized with a mixture of ketamine and xylazine (100 mg/
kg and 20 mg/kg, respectively). After the pupils were dilated 
with 1% tropicamide, electroretinographic (ERG) recordings 
of the B6 mice were obtained (Espion Electroretinography 
System; Diagnosys LLC, Lowell, MA). One active electrode 
(a gold wire loop) was placed on the cornea, and then an elec-
trode was placed on the head, to serve as a reference. Another 
electrode was placed on the back, serving as the ground. 
The ERG responded to a series of increasing-intensity light 
flashes presented in a Ganzfeld bowl (UTAS3000; LKC 
Technologies): 0.1, 1.0, 3.0, and 10.0 dB, which were averaged 
over ten separate flashes per light intensity. The amplitude of 
the a-wave was defined as the absolute value from the base-
line to the trough of the first negative wave. The amplitude 
of the b-wave was defined as the absolute value from the 
trough of the a-wave to the peak of the first positive wave. 
If the a-wave was absent, the baseline to the peak of the first 
positive wave was measured. During the entire procedure, 
the body temperature of the mice was maintained by using a 
water heating pad.
Cell counting and survival evaluation: Cell counting was 
performed by counting the total number of cells that remained 
in the subretinal space of each field in every one in four serial 
sections through the site of injection in each eye. This was 
multiplied by the total number of sections that encompassed 
the injection site to give an estimate of the mean number of 
integrated cells per eye.
Statistical analysis: The data were expressed as the mean 
± standard deviation (SD; n = 15). The Mann–Whitney U 
test was used to compare the data between the two groups. 
Statistical significance was defined at p<0.05.
RESULTS
Spectral domain optical coherence tomography: SDOCT 
serves as noninvasive monitoring of the initial detachment 
in our study. The subretinal injection of the hRPCs resulted 
in a local retinal detachment, which could be detected with 
SDOCT. Figure 1 shows a series of SDOCT images at 
different points in time before the eyes were sectioned, illus-
trating the injection site and the retinal bleb of the two groups. 
Immediately after the cells were injected, a significant bleb 
was evident in the injected cells visible in the subretinal space 
(Figure 1B). Three days later, the original bleb decreased 
for both groups, with no obvious difference (Figure 1C,D). 
However, 1 week later, the size of the bleb was significantly 
reduced, although the medium size of the retinal detachment 
remained (Figure 1E,F). At the 3-week point, most mice 
showed no obvious evidence of retinal detachment in either 
group (Figure 1G,H). Among different individuals, the size of 
the initial bleb and the range of the detachment varied, even 
with the same surgery process and the same injection param-
eters (total volume, number of cells, flow rate of injection).
To make comparisons of the SDOCT images before and 
after injection, retinal thicknesses were measured from the 
peak of the retinal detachment bleb at the interface with the 
vitreous body to the basal RPE, including all retinal layers. 
Measurements at each injection location were made at the 
same site before and at different time points after injec-
tion. The results showed that the total retinal thickness was 
reduced by an average of 3% by 3 days, 10% by 1 week, and 
5% by 3 weeks after injection. Figure 1 shows evidence of the 
thinning of the nerve fiber layer and the inner plexiform layer 
in the retinal cross-sectional image of the SDOCT taken at 
different time points before and after injection.
Histology: To evaluate the histological changes in the hRPCs 
under the systemic administration of CsA, GFP-positive 
hRPCs were injected into the B6 mice as a cell suspension in 
the subretinal space. The grafted GFP-positive hRPCs were 
observed suspended in the subretinal space as soon as they 
were injected into the recipient eyes, through both in vivo 
fundoscopy (not shown) and histological analyses (Figure 2, 
Figure 3, Figure 4). In addition, the hRPCs maintained a high 
level of expression of GFP, allowing easy identification of 
not only the cell bodies but also the processes. Compared 
with the cells that congregated together immediately after 
the injection, one could determine that the GFP-positive cells 
began to distribute evenly in the subretinal space around 
the injection site after 3 days (Figure 2F,I,J). There was no 
obvious difference between the control group and the CsA 
group (p>0.05); moreover, none were present within the 
host retina in either group. The picture shows the area of Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
1274
bleb formation and retinal detachment due to the delivery of 
the transplanted cells into the subretinal space. Similarly, 1 
week after transplantation, a cluster of hRPCs remained in 
the subretinal space, and the survival rate decreased for both 
groups (Figure 3C,F,G; p<0.05).
The GFP expression decreased over time following the 
in vitro transplantation (possibly due to an immune reac-
tion). The gap in the survival rate between the two groups 
increased, with the cells surviving in the CsA group, as 
opposed to the control group. Three weeks after transplanta-
tion, the grafted GFP positive hRPCs were still evident, and 
resided in the subretinal space (Figure 4C,F,G) with faint 
expression. Compared with the control group, the cells in the 
CsA group survived better, with most remaining cells in the 
subretinal space (p<0.05). However, a few cells migrated into 
the host retinal layers.
ERG analysis: The retinal function in this study was 
measured using ERG and analyzed (Figure 5 and Figure 6). 
The data from the ERG response stimulated with different 
flash intensities were collected under dark-adapted and 
light-adapted conditions, respectively. Therefore, the figure 
shows the data at the baseline (before injection) and at 1 and 
3 weeks after injection. In the dark-adapted condition, no 
obvious difference between the CsA group and the control 
group was observed at 1 week (p = 0.40). However, the CsA 
group was much less influenced by the injection (p=0.114), 
which showed a statistically non-significant decrease from 1 
week to 3 weeks (t = 0.531, p = 0.614), while the control group 
showed a larger decrease in the mean amplitude from 1 week 
to 3 weeks (p = 0.040).
In the light-adapted condition, the ERG amplitude 
showed a significant decrease after the injection at 1 week in 
Figure 1. Cross-sectional spectral 
domain optical coherence tomog-
raphy images for two groups of 
eyes over a time period of 3 weeks. 
The images before the injection (A; 
n=10) and immediately after the 
injection (B; n=10) were followed 
up by scans at 3 days (C, D; n=30), 
1 week (E, F; n=30), and 3 weeks 
(G, H; n=30). The Cyclosporin A 
(CsA) group (C, E, G; n=45) and 
the control group (D, F, H; n=45) 
showed the same trend in changes 
in the bleb: A distinct bleb with 
retinal detachment appeared imme-
diately after cell injection and after 
3 days. One week after injection, 
the initial bleb settled down, but 
the retinal detachment space was 
still evident (arrows in E, F). Three 
weeks after injection, the retina 
appeared normal without evident 
retinal detachment (arrows in G, 
H). The scale bar is 50 μm.Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
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Figure 2. Three days after human 
retinal progenitor cells were 
injected into the subretinal space 
in B6 mice. The first row (A, B, 
C) represents the moment imme-
diately after injection (n=10). The 
second row (D, E, F) shows the 
Cyclosporin A (CsA)-treated group 
(n=15). The third row (G, H, I) 
is the human retinal progenitor 
cell (hRPC) groups as the control 
(n=15). J: The average number of 
cells in the subretinal space was 
counted per microscopic field. The 
columns are the mean values, and 
the error bars are standard devia-
tion (SD). * There was no obvious 
difference between the control 
group and the CsA group (p>0.05; 
n = 15). Scale bar = 50 μm. Abbre-
viations: outer nuclear layer (ONL); 
subretinal space (SRS).Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
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both groups (p =0.04, p = 0.001, for the non-CsA and CsA, 
respectively). However, the cone ERG function was almost 
recovered in the CsA group (p = 0.534). Compared to the 
light-adapted condition, the response amplitudes in the dark-
adapted condition, mediated by the rods, decreased signifi-
cantly from the baseline 1 week after injection, while the 
light-adapted ERG, mediated by the cones, was less affected. 
The dark-adapted ERG and the light-adapted ERG improved 
over time, but 3 weeks after transplantation, the ERG ampli-
tudes were hard to recover to the baseline measurements (p 
= 0.008, p = 0.044, for the non-CsA and CsA, respectively).
DISCUSSION
With the combination of noninvasive and invasive methods 
applied in our study, we monitored the retinal structural and 
functional changes when the hRPCs were injected into the 
subretinal space in the wild-type mice, after 3 weeks of treat-
ment with CsA. Recovery from the initial blebs was observed 
in the live animals with the implementation of SDOCT, while 
the resulting histological and functional changes in transplan-
tation were analyzed using confocal microscopy and ERG.
Recently, retinal progenitor cells have received consider-
able attention as novel and feasible tools in the quest to restore 
sight in cases of retinal degeneration, and certainly hold great 
Figure 3. Seven days after human 
retinal progenitor cells were 
injected into the subretinal space 
in B6 mice. The first row (A, 
B, C) shows the Cyclosporin A 
(CsA)-treated group after injection 
(n=15). The second row (D, E, F) 
are the human retinal progenitor 
cell (hRPC) groups as the control 
(n=15). G: The average number of 
cells in the subretinal space was 
counted per microscopic field. 
The columns are the mean values, 
and the error bars are standard 
deviation (SD). A cluster of hRPCs 
remained in the subretinal space, 
and the survival rate decreased 
for both groups, but still showed a 
difference (p<0.05; n = 15). Scale 
bar = 50 μm. Abbreviations: outer 
nuclear layer (ONL); subretinal 
space (SRS).Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
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potential as a promising cell-based approach for photore-
ceptor degeneration [20-22]. Since mice and humans share a 
significant number of conservative properties for retinal stem 
cells, there is no distinct species difference between stem 
cells, which demonstrates the possibility for the therapeutic 
potential of human RSCs [20,21,23]. The systemic adminis-
tration of CsA is now widely used in the clinical treatment 
of ophthalmic diseases, suppressing the immune response 
by blocking the signal transduction pathway responsible for 
activating B-lymphocytes and T-lymphocytes [12-14].
The results of our study prompted us to discuss some 
possible mechanisms taking place. First, disrupted by subret-
inal injection, the balance of the subretinal microenvironment 
previously regarded as an immunoprivileged site was broken 
[24]. Second, CsAs may induce the overexpression of cell 
factors, such as transforming growth factor-β (TGF-β; a fibro-
genic cytokine), which eventually act as immunosuppressants 
against rejection after transplantation [25]. Third, retinal 
progenitor cells, in general, have been shown to possess low 
immunogenicity, which may protect them from T-cell recog-
nition, allowing them to survive in hosts for extended periods 
of time [26]. In the ocular microenvironment, immunosup-
pressive factors, including TGF-β, FasL, and IDO, produced 
by the RPCs, contribute in part to the immunoprivileged (IP) 
properties [24,27]. Finally, the synergistic effects of retinal 
progenitor cells and the implementation of CsA induce 
Figure 4. Three weeks after human 
retinal progenitor cells were 
injected into the subretinal space 
in B6 mice. The first row (A, B, 
C) represents the Cyclosporin A 
(CsA)-treated group after injection 
(n=15). The second row (D, E, F) 
is human retinal progenitor cells 
(hRPCs) groups as the control 
(n=15). G: The average number of 
cells in the subretinal space was 
counted per microscopic field. 
The columns are the mean values, 
and the error bars are standard 
deviation (SD). Compared with the 
control group, the cells in the CsA 
group survived better, with most 
remaining cells in the subretinal 
space (p<0.05; n = 15). Scale bar 
= 50 μm. Abbreviations: ganglion 
cell layer (GCL); inner nuclear layer 
(INL); outer nuclear layer (ONL); 
subretinal space (SRS).Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
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suppression in the recipient’s immune response, making it 
possible to increase the survival rate after 3 weeks. The fact 
that the hRPCs survived better under the treatment of CsA for 
3 weeks in our study, postinjection, supports hRPC transplan-
tation and shows promising potential as a feasible cell source 
for transplantation. RPCs can be delivered to the retina in 
different ways (intravenous, intravitreal, and subretinal) and 
in different forms (suspension versus sheets of cells) [28,29]. 
In our study, we chose the injection of hRPCs as a single 
cell suspension, which imposes certain stresses on the graft, 
which may result in cell death and a poor survival rate.
Although we have shown a statistical difference between 
the CsA and non-CsA groups, the substantial number of 
hRPCs left in the subretinal space in both groups still mani-
fested a huge decrease after 3 weeks. There are some possible 
reasons for this. First, the B6 mice did not have an incentive 
environment for cell survival. Instead, it may have released 
immunoreactive factors to resist the donor cells living in the 
subretinal space. It may be helpful to perform transplanta-
tion with the CsA either directly injected into the subretinal 
space or via a controlled release system in the future. Second, 
because of the regression of the cells at the injection site, 
the donor cells left in the spot would be greatly decreased. 
Figure  5.  Electroretinography 
recordings from B6 mice in dark-
adapted and light-adapted condi-
tions at baseline, 1 week, and 3 
weeks. The b-wave and a-wave 
response amplitudes in the Cyclo-
sporin A (CsA) group (n=30) were 
less decreased than the control 
group (n=30) after injection in the 
dark-adapted and light-adapted 
conditions.
Figure 6. Comparison of electro-
retinography recordings in the 
dark-adapted and light-adapted 
conditions. A: Dark-adapted (rod-
mediated) electroretinography 
(ERG) responses. B: Light-adapted 
(cone-mediated) ERG responses. 
Electroretinography was performed 
on mice before the injections, 1 
week, and 3 weeks after injections. 
The dark- and light-adapted ERG 
recordings were performed on the 
same mice. The ERG response 
amplitudes in the Cyclosporin A 
(CsA) group were less reduced after the injection (p=0.114; p=0.01; in the dark-and-light-adapted conditions respectively), when compared 
with the control group (p=0.040; p=0.04; in the dark-and-light-adapted conditions, respectively), in both the dark-adapted and light-adapted 
conditions. However, the cone-mediated function in both groups was less affected by the transplantation after 3 weeks than the rod-mediated 
function p = 0.008; p = 0.044, for the non-CsA and CsA, respectively).Molecular Vision 2014; 20:1271-1280 <http://www.molvis.org/molvis/v20/1271> © 2014 Molecular Vision 
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Therefore, improvement in the delivery methods, such as 
seeding hRPCs on scaffolds, may cushion the stress placed 
on the grafted cells and increase the survival rate.
SDOCT was selected as a noninvasive approach for 
detecting the bleb of retinal detachment with mouse eyes, 
allowing us to monitor the advancement of the reattachment 
postinjection. Compared to the approach adapted in several 
studies [30,31], it has been shown that good reproducibility 
for SDOCT of retinal measurements in mice could be used 
as a promising technology following retinal detachment, 
and outer retinal abnormalities in a murine model. The flat-
tening of the blebs after 3 weeks, observed in most of the 
mice, showed that the time taken for reattachment could be 
an important parameter in evaluating the recovery of retinal 
structure and function [32-35].
The change in the retinal function postinjection was 
evaluated using ERG in our study. There was no obvious 
difference between the two groups in the light-adapted 
conditions after 3 weeks, indicating that the cone function 
was less affected by the injection. Although the visual cycle 
was disrupted by transplantation, the cone function showed 
less dependence on the relationship with the RPE, since it 
initiates an alternate visual pathway responsible for sustained 
daylight vision, and thus, it may be less influenced [36]. The 
decrease in the ERG amplitude shortly after injection is likely 
due to the separation of the sensory retina from the retinal 
pigment epithelium. However, it has been shown that the CsA 
group recovered better after 3 weeks, demonstrating that the 
rod-mediated function under dark-adapted conditions was 
affected more by the surgery, and that the CsA could alleviate 
the trauma of the sham surgery to some extent. Neither the 
scotopic nor photopic functions recovered to their original 
conditions by 3 weeks after injection, probably due to the 
photoreceptor cell loss, especially near the injection site.
In conclusion, our study shows that the combination of 
hRPCs and CsA treatment made it possible for the xenograft 
cells to survive better. The differentiation and migration in 
retinal degenerative mice, under the treatment of CsA, require 
further investigation.
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